This topic contains a solution. Click here to go to the answer

Author Question: A neonate receiving inhaled nitric oxide (iNO) for the treatment of persistent pulmonary ... (Read 35 times)

geoffrey

  • Hero Member
  • *****
  • Posts: 880
A neonate receiving inhaled nitric oxide (iNO) for the treatment of persistent pulmonary hypertension is receiving 80 ppm of iNO, and an Fio2 of 0.80. What should be the therapist's concern in this situation?
 
  A. that the patient will develop O2 toxicity
  B. that the patient will develop ventilator induced lung injury
  C. that the patient will develop rebound vasoconstriction
  D. that the patient will develop methemoglobinemia

Question 2

How is methemoglobinemia treated?
 
  A. infusion of methylene blue
  B. decreased doses of iNO
  C. infusion of NADH methemoglobin reductase
  D. increasing the Fio2



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

TINA

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

ANS: C
A. Incorrect response: See explanation C.
B. Incorrect response: See explanation C.
C. Correct response: Methemoglobin (metHb) results when the iron atom in heme is oxidized from Fe2+ (ferrous ion) to Fe3+ (ferric ion). In the ferric state (oxidized form), iron is incapable of binding with O2, and the affinity of other heme groups for O2 increases (i.e., shifts the oxyhemoglobin curve to the left). The normal methemoglobin blood level (<2) may be due in part to metabolism of endogenous NO. Methemoglobin reductase within erythrocytes converts endogenously produced methemoglobin to normal hemoglobin. Methemoglobinemia is uncommon at the NO doses used for therapeutic (20 ppm) inhalation. A few cases of methemoglobinemia have been reported in association with iNO therapy, generally with high doses of iNO (e.g., 80 or more ppm). In patients with decreased methemoglobin reductase, methemoglobinemia will be more likely.
D. Incorrect response: See explanation C.

Answer to Question 2

ANS: A
A. Correct response: The usual treatment of methemoglobinemia is infusion of methylene blue, which increases NADH methemoglobin reductase. Methemoglobinemia can also be treated with ascorbic acid (vitamin C). The production of methemoglobin in patients treated with iNO is dose-dependent; methemoglobinemia is rare at usual therapeutic doses of less than 20 ppm.
B. Incorrect response: See explanation A.
C. Incorrect response: See explanation A.
D. Incorrect response: See explanation A.





 

Did you know?

Elderly adults are living longer, and causes of death are shifting. At the same time, autopsy rates are at or near their lowest in history.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

The liver is the only organ that has the ability to regenerate itself after certain types of damage. As much as 25% of the liver can be removed, and it will still regenerate back to its original shape and size. However, the liver cannot regenerate after severe damage caused by alcohol.

Did you know?

In most cases, kidneys can recover from almost complete loss of function, such as in acute kidney (renal) failure.

Did you know?

Ether was used widely for surgeries but became less popular because of its flammability and its tendency to cause vomiting. In England, it was quickly replaced by chloroform, but this agent caused many deaths and lost popularity.

For a complete list of videos, visit our video library